Balasa Dinverno & Foltz’s United Therapeutics UTHR Stock Holding History

Balasa Dinverno & Foltz’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$665K	Sell	3,175 -32	-1%	-$7.15K	0.04%	171
2022 Q2	$756K	Sell	3,207 -442	-12%	-$89.9K	0.05%	152
2022 Q1	$655K	Sell	3,649 -541	-13%	-$103K	0.04%	171
2021 Q4	$905K	Sell	4,190 -58	-1%	-$11.4K	0.06%	139
2021 Q3	$784K	Sell	4,248 -301	-7%	-$59.3K	0.05%	140
2021 Q2	$816K	Sell	4,549 -590	-11%	-$112K	0.06%	135
2021 Q1	$860K	Buy	5,139 +1,618	+46%	+$270K	0.07%	128
2020 Q4	$534K	Sell	3,521 -3,206	-48%	-$421K	0.04%	163
2020 Q3	$679K	Buy	6,727 +1,353	+25%	+$148K	0.06%	128
2020 Q2	$650K	Buy	+5,374	New	+$605K	0.07%	116
2018 Q4	–	Sell	-2,034	Closed	-$260K	–	248
2018 Q3	$260K	Buy	+2,034	New	+$252K	0.03%	204
2017 Q2	–	Sell	-2,559	Closed	-$346K	–	213
2017 Q1	$346K	Buy	+2,559	New	+$388K	0.06%	141

Other funds holding UTHR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Balasa Dinverno & Foltz's UTHR Position: Q3 2022 in Review

Balasa Dinverno & Foltz reduced its United Therapeutics (UTHR) stake by 1% in Q3 2022, selling an estimated $7.15K and leaving 3,175 shares worth $665K. The position accounts for 0.04% of the portfolio, ranked #171.

Balasa Dinverno & Foltz first reported a position in UTHR in Q1 2017 and has held it in 12 quarters since. The position peaked at $905K in Q4 2021. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

Balasa Dinverno & Foltz held 3,175 shares of United Therapeutics worth $665K as of Q3 2022.
Balasa Dinverno & Foltz sold 32 United Therapeutics shares in Q3 2022, an estimated $7.15K.
United Therapeutics made up 0.04% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #171 holding.
Balasa Dinverno & Foltz first reported a position in United Therapeutics in Q1 2017 and has held it in 12 quarters since.
Balasa Dinverno & Foltz's United Therapeutics position peaked at $905K in Q4 2021.
461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.